In this role, Dr Fox will assume responsibility for regulatory affairs, pharmacovigilance and medical affairs. Clinical operations will continue to report to the medical director, Brett Charlton.
Dr Fox was most recently with Novartis as a global brand medical director and previously held the positions of senior clinical research physician and principle medical expert for Novartis.
Alan Robertson, CEO of Pharmaxis, said: “The appointment of Howard Fox provides the international regulatory and pharmacovigilance experience necessary for Pharmaxis to bring Bronchitol successfully and rapidly to the market and we are very much looking forward to his contribution.”